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OBJECTIVES The study goals were to: 1) define the relationship between body mass index (BMI) and
insulin resistance in 314 nondiabetic, normotensive, healthy volunteers; and 2) determine the
relationship between each of these two variables and coronary heart disease (CHD) risk
factors.
BACKGROUND The importance of obesity as a risk factor for type 2 diabetes and hypertension is
well-recognized, but its role as a CHD risk factor in nondiabetic, normotensive individuals is
less well established.
METHODS Insulin resistance was quantified by determining the steady-state plasma glucose (SSPG)
concentration during the last 30 min of a 180-min infusion of octreotide, glucose, and insulin.
In addition, nine CHD risk factors: age, systolic blood pressure, diastolic blood pressure
(DBP), total cholesterol, triglycerides (TG), high-density lipoprotein (HDL) cholesterol and
low-density lipoprotein cholesterol concentrations, and glucose and insulin responses to a
75-g oral glucose load were measured in the volunteers.
RESULTS The BMI and the SSPG concentration were significantly related (r 0.465, p 0.001). The
BMI and SSPG were both independently associated with each of the nine risk factors. In
multiple regression analysis, SSPG concentration added modest to substantial power to BMI
with regard to the prediction of DBP, HDL cholesterol and TG concentrations, and the
glucose and insulin responses.
CONCLUSIONS Obesity and insulin resistance are both powerful predictors of CHD risk, and insulin
resistance at any given degree of obesity accentuates the risk of CHD and type 2
diabetes. (J Am Coll Cardiol 2002;40:937–43) © 2002 by the American College of
Cardiology Foundation
Results of the Third National Health and Nutrition Exam-
ination Survey (NHANES III) have documented the fact
that obesity has become a national epidemic (1). The
importance of obesity as a risk factor for type 2 diabetes (2)
and hypertension (3) has been well recognized, but its role
as a coronary heart disease (CHD) risk factor in nondia-
betic, normotensive individuals has been less well estab-
lished. In this context, two issues seemed worthy of inves-
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tigation in order to define more clearly the relationship
between obesity and CHD. Although insulin resistance is
often considered to be the link between obesity and type 2
diabetes, hypertension, and CHD risk, there is evidence
that obese and overweight individuals can also be insulin-
sensitive (4–6). Thus, the first goal of this study was to
define the relationship between resistance to insulin-
mediated glucose disposal and body mass index (BMI) in a
large group of healthy, nondiabetic volunteers.
Our second goal was to clarify the relative impact of
obesity, per se, as distinguished from insulin resistance, on
CHD risk factors. Given the difficulty in achieving success
in weight control programs (7), it would be helpful to
identify a subset of obese individuals who would benefit the
most from weight loss and, therefore, be given the highest
priority in weight loss programs.
The present report describes the relationship between
BMI and insulin resistance in 314 nondiabetic, normoten-
sive, healthy volunteers and defines the association of
conventional CHD risk factors with obesity and insulin
resistance.
METHODS
The data to be analyzed represent information gathered on
314 volunteer subjects, 186 women and 128 men, who had
participated in our research studies from 1990 to 1998.
Subjects included in the evaluation had no history of
diabetes, CHD, or hypertension. In addition, they had
normal findings upon physical examination and routine
laboratory tests and were nondiabetic (8). The majority of
participants were Caucasian (77%), with a small percentage
of individuals of Asian (12%), Hispanic (10%), and African
ancestries (1%). The volunteers had a mean  SD age of 46
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 13 years (range, 19 to 79) and BMI of 25.2  3.8 kg/m2
(range, 18.5 to 34.6).
Subjects were weighed on an electronic scale to the
nearest 0.01 kg in hospital garments, height was measured
to the nearest 0.01 cm without shoes, and BMI was
calculated by dividing weight in kilograms by the square of
the height in meters. Fasting plasma glucose and insulin
concentrations were measured before and 30, 60, 120, and
180 min after the ingestion of a 75-g oral glucose challenge.
The total integrated glucose and insulin responses were
quantified by calculating the glucose and insulin area under
the curve by use of the trapezoidal method. The analytical
methods used for determining plasma glucose and insulin
concentrations were similar over the duration of the study,
as were those used for the determination of fasting concen-
trations of total cholesterol, triglycerides (TG), high-density
lipoprotein (HDL) cholesterol, and low-density lipoprotein
(LDL) cholesterol (9–11). Insulin-mediated glucose dis-
posal was estimated by a modification of the insulin sup-
pression test (12) as introduced and validated by our
research group (13). After an overnight fast, an intravenous
catheter was placed in each arm of the patient. One arm was
used for the administration of a 180-min infusion of
octreotide, insulin, and glucose, and the other arm was used
for collecting blood samples. Blood was sampled every 30
min initially and then at 10-min intervals from 150 to 180
min of the infusion to determine the steady-state plasma
insulin (SSPI) and glucose concentrations for each individ-
ual. Because SSPI concentrations are similar for all subjects,
the steady-state plasma glucose (SSPG) concentration pro-
vides a direct measure of the ability of insulin to mediate
disposal of an infused glucose load; the higher the SSPG,
the more insulin-resistant is the individual.
The population was divided into three categories of BMI
as proposed by the National Institutes of Health (14):
normal weight (18.5 to 24.9 kg/m2); overweight (25.0 to
29.9 kg/m2); and obesity class I (30.0 to 34.9 kg/m2). When
this was done, our study population closely resembled the
distribution of BMI in NHANES III, containing 52.5%,
32.1%, and 15.3% of individuals defined as being normal
weight, overweight, and obese (15), compared with values of
43.6%, 32.6%, and 14.3%, respectively, for the same groups
in NHANES III (1,15).
Data are expressed as mean  SE. In each of the three
BMI categories, means of BMI, SSPG, and the nine CHD
risk factors (age, systolic blood pressure [SBP], diastolic
blood pressure [DBP], total cholesterol, TG, HDL choles-
terol, LDL cholesterol, glucose response, and insulin re-
sponse) were compared using one-way analysis of variance.
The relationship between BMI and SSPG concentration
was depicted in the form of a scatter plot, and Pearson and
Spearman correlation coefficients were calculated. Individ-
uals were defined as insulin-sensitive and insulin-resistant if
they were in the lower (SSPG 4.66 mmol/l) and upper
(SSPG 8.38 mmol/l) SSPG tertiles of the sample, respec-
tively.
Simple and partial (adjusting for sex) correlation coeffi-
cients were calculated, first between each of the nine CHD
risk factors and BMI, and then between each of the nine
CHD risk factors and SSPG.
Multiple regression analyses were performed to evaluate
whether the prediction of each of the nine CHD risk factors
from the level of BMI would be modified if the degree of
insulin resistance (SSPG) and an interaction between obe-
sity (BMI) and insulin resistance (SSPG) were known in
addition to the BMI. Two regression models were em-
ployed to evaluate these relationships. In model A, each risk
factor was regressed on BMI and SSPG jointly. In model B,
each risk factor was regressed on BMI, SSPG, and an
interaction term. The interaction term was calculated by
multiplying BMI and SSPG for each individual. Further-
more, using the results of regression model B, each of the
nine CHD risk factors and BMI were graphed as continu-
ous variables, while holding SSPG constant at three levels,
namely, the means of the lower (insulin-sensitive), interme-
diate, and upper (insulin-resistant) SSPG tertiles of the
sample.
RESULTS
The demographic characteristics of three obesity categories
are listed in Table 1, as are the values for SSPG concentra-
tion. The ages and gender distributions of the three groups
were similar. The BMI values were significantly different,
and the higher the BMI category, the greater the SSPG
concentration (p  0.05). Table 1 also presents the values
for the CHD risk factors assessed in the three experimental
groups, and it can be seen that all of these variables worsen
as BMI increases.
The relationship between BMI and SSPG concentration
in the entire population is shown in Figure 1. Although the
Pearson correlation coefficient between the two variables
was of statistically significant (r  0.465, p  0.001)
magnitude, only 22% (r2) of the variability in SSPG
concentrations within this sample could be attributed to the
association with BMI. It should be noted that the nonpara-
metric (Spearman correlation coefficient) relationship be-
Abbreviations and Acronyms
BMI  body mass index
CHD  coronary heart disease
DBP  diastolic blood pressure
EGIR  European Group for the Study of Insulin
Resistance
HDL  high-density lipoprotein
LDL  low-density lipoprotein
NHANES  National Health and Nutrition
Examination Survey
SBP  systolic blood pressure
SSPG  steady-state plasma glucose
SSPI  steady-state plasma insulin
TG  triglycerides
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tween the two variables was similar in magnitude (  0.
441, p  0.001). Furthermore, SSPG values varied widely
across the BMI range; obese individuals (BMI 30.0
kg/m2) were insulin-sensitive, and insulin resistance oc-
curred in normal weight individuals (BMI 25.0 kg/m2).
Indeed, approximately 25% of insulin-resistant individuals
were of normal weight, and the same proportion was obese.
Table 2 shows the simple and partial (adjusting for sex)
correlation coefficients between BMI and SSPG and each of
the nine CHD risk factors. Although these relationships
were all statistically significant, there were notable differ-
ences in their magnitude. The BMI correlations were higher
than SSPG correlation for age, SBP, total cholesterol, and
LDL cholesterol. On the other hand, SSPG correlations
were higher for DBP, TG, HDL cholesterol, glucose
response, and insulin response. It should be noted that these
findings did not change when adjusted for differences in sex.
Table 3 shows the results of multiple regression analyses
when the relationships between each CHD risk factor and
BMI and SSPG were further quantified. The results using
model A show that BMI was an independent predictor of
SBP, total cholesterol, and LDL cholesterol concentrations,
whereas SSPG was not. Conversely, SSPG was an indepen-
dent predictor of DBP and glucose response, whereas BMI
was not. Furthermore, both BMI and SSPG were indepen-
dent predictors of TG, HDL cholesterol, and insulin
response; however, SSPG was a stronger predictor of these
risk factors as indicated by higher, and statistically signifi-
cant, standardized regression coefficient values. Finally, the
results of regression model B provide additional insights
into these relationships, showing that the interaction term
was the only independent predictor of glucose response and
insulin response, whereas the interaction term, SSPG, and
BMI all independently predicted HDL cholesterol.
The results of multiple regression analyses using model B
are graphically presented in Figure 2. In each panel, the
regression lines describe the expected CHD risk factor as a
function of obesity (BMI) at the mean SSPG concentration
for the insulin-resistant (11.68 mmol/l), intermediate (6.33
mmol/l), and insulin-sensitive (3.37 mmol/l) SSPG tertiles.
Table 1. Demographic and Metabolic Characteristics of Volunteers by BMI Group
Variable Normal Weight (n  165) Overweight (n  101) Obesity Class I (n  48) p Value
Age (yrs) 44  1 (19–79) 48  1 (19–71) 47  2 (26–75) 0.1
Gender (female/male %) 61/39 55/45 60/40 0.64
BMI (kg/m2) 22.2  0.1 (18.5–24.9) 27.0  0.1 (25.0–29.9) 31.7  0.2 (30.0–34.6)  0.001
SSPG (mmol/l) 5.57  0.20 (1.89–13.99) 8.34  0.41 (1.39–17.15) 9.82  0.61 (2.89–18.43)  0.05
SBP (mm Hg) 114  1 (82–139) 118  1 (90–139) 121  1 (104–139)  0.01
DBP (mm Hg) 71  1 (48–89) 74  1 (50–89) 73  1 (52–88) 0.03
Total cholesterol (mmol/l) 4.51  0.07 (2.10–6.76) 5.02  0.09 (3.08–7.77) 5.15  0.13 (3.52–7.80)  0.001
TG (mmol/l) 0.92  0.04 (0.29–5.01) 1.34  0.06 (0.37–2.99) 1.69  0.13 (0.52–5.07)  0.001
HDL cholesterol (mmol/l) 1.43  0.03 (0.60–2.51) 1.26  0.03 (0.73–2.36) 1.13  0.03 (0.73–1.74)  0.001
LDL cholesterol (mmol/l) 2.69  0.06 (1.08–4.77) 3.15  0.08 (1.42–6.28) 3.26  0.13 (1.79–5.57)  0.001
Glucose response (mmol/l3 h) 17.07  0.26 (10.24–28.35) 18.92  0.35 (9.98–29.76) 19.58  0.71 (11.38–34.13)  0.001
Insulin response (pmol/l3 h) 809  33 (139–2,580) 1,214  85 (365–4,990) 1,682  214 (346–8,523)  0.001
Data are given as mean  SE (range) or percentage of subjects; p value is for the differences among the three BMI groups by one-way analysis of variance, except for gender
distribution differences, calculated using chi-square test.
BMI  body mass index; DBP  diastolic blood pressure; HDL  high-density cholesterol; LDL  low-density cholesterol; SBP  systolic blood pressure; SSPG 
steady-state plasma glucose; TG  triglycerides.
Figure 1. Relationship between body mass index and steady-state plasma
glucose.
Table 2. Simple and Partial Correlation Coefficients (r) Between
Coronary Heart Disease Risk Factors, BMI, and SSPG
Risk Factors
BMI SSPG
Simple Partial Simple Partial
Age 0.189* 0.180* 0.106† 0.113*
SBP 0.286 0.278 0.160* 0.168*
DBP 0.139* 0.125* 0.202 0.216
Total cholesterol 0.348 0.349 0.242 0.243
TG 0.444 0.437 0.507 0.520
HDL cholesterol 0.385 0.382 0.410 0.461
LDL cholesterol 0.361 0.355 0.223 0.229
Glucose response 0.306 0.303 0.573 0.577
Insulin response 0.380 0.379 0.630 0.631
Partial correlation coefficients were calculated after adjusting for differences in gender;
all p values are 0.001 except for *p  0.05 and †p  0.16.
BMI  body mass index; DBP  diastolic blood pressure; HDL  high-density
cholesterol; LDL  low-density cholesterol; SBP  systolic blood pressure; SSPG 
steady-state plasma glucose; TG  triglycerides.
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The figure shows that increasing levels of SSPG did not
particularly modify the predicted SBP, LDL cholesterol,
and total cholesterol. On the other hand, the predicted
DBP, glucose response, and more strikingly, TG, HDL
cholesterol, and insulin response were clearly higher at the
insulin-resistant SSPG concentration.
DISCUSSION
Relationship between obesity and insulin resistance.
The results of the current, population-based study provide
additional insight into the relationship between obesity and
insulin resistance and are reasonably similar to the only
published study (4) in which this relationship has been
evaluated in a large number of individuals using a specific
method to determine insulin-mediated glucose disposal. In
addition to supporting previous results (16–18) that differ-
ences in weight modulate insulin action, the data presented
provide a quantitative estimate of the role of obesity in
regulating insulin-mediated glucose disposal. The relation-
ship between BMI and SSPG shown in Figure 1 and Table
1 indicates that only approximately 22% of the variability in
SSPG concentration (r2) in this healthy volunteer popula-
tion can be attributed to differences in BMI, an estimate
that is consistent with the report (4) of the European Group
for the Study of Insulin Resistance (EGIR). This group
quantified insulin action in 1,146 nondiabetic, normotensive
individuals with the euglycemic, hyperinsulinemic clamp,
and it also defined insulin resistance as the value of
insulin-mediated glucose disposal in the lowest 10% of the
normal weight population (BMI 25.0 kg/m2). With this
criterion they found 26% of the obese individuals (BMI 
29.0 kg/m2) to be insulin-resistant. This estimate is similar
Table 3. Multiple Regression Analysis of the Relationship Between the CHD Risk Factors
With BMI and SSPG Jointly, Without an Interaction Term (Model A) and With the
Interaction Term (Model B)
CHD Risk Factors
Model A Model B
BMI SSPG BMI SSPG BMI  SSPG
Age RA  0.190 RB  0.190
 0.178 0.023 0.183 0.043 0.023
SE 0.215 0.012 0.428 0.076 0.003
p 0.005 0.711 0.145 0.915 0.961
SBP RA  0.288 RB  0.290
 0.27 0.035 0.205 0.207 0.280
SE 0.185 0.01 0.368 0.066 0.002
p 0.001 0.573 0.094 0.601 0.537
DBP RA  0.208 RB  0.210
 0.058 0.175 0.105 0.349 0.202
SE 0.143 0.008 0.284 0.051 0.002
p 0.357 0.006 0.401 0.388 0.663
Total cholesterol RA  0.358 RB  0.359
 0.301 0.098 0.244 0.103 0.235
SE 0.561 0.032 1.115 0.198 0.007
p 0.001 0.117 0.049 0.788 0.596
TG RA  0.556 RB  0.557
 0.260 0.382 0.196 0.154 0.267
SE 0.860 0.049 1.709 0.302 0.011
p 0.001 0.001 0.077 0.655 0.501
HDL cholesterol RA  0.463 RB  0.477
 0.246 0.293 0.468 1.08 0.922
SE 0.195 0.011 0.386 0.068 0.003
p 0.001 0.001 0.001 0.003 0.029
LDL cholesterol RA  0.365 RB  0.366
 0.330 0.065 0.347 0.128 0.073
SE 0.505 0.029 1.009 0.179 0.007
p 0.001 0.292 0.005 0.740 0.870
Glucose response RA  0.575 RB  0.584
 0.051 0.549 0.144 0.171 0.836
SE 0.947 0.052 1.872 0.334 0.012
p 0.332 0.001 0.165 0.609 0.030
Insulin response RA  0.638 RB  0.649
 0.110 0.579 0.123 0.283 0.999
SE 1.628 0.090 3.203 0.571 0.021
p 0.026 0.001 0.208 0.368 0.006
  standardized regression coefficient; BMI  body mass index; CHD  coronary heart disease; DBP  diastolic blood
pressure; HDL  high-density cholesterol; LDL  low-density cholesterol; RA  multiple correlation coefficient for model A;
RB  multiple correlation coefficients for model B; SBP  systolic blood pressure; SSPG  steady-state plasma glucose; TG 
triglycerides.
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to our finding that only 25% of our population in the upper
tertile of insulin resistance had a BMI30.0 kg/m2. Similar
quantitative estimates of the magnitude of the relationship
between obesity and insulin resistance can be found in a
case-control study involving both Pima Indians and Cau-
casians (18) in which approximately 25% of the variability in
insulin action could be ascribed to differences in body
weight. Because these studies excluded patients with diabe-
tes and/or hypertension, syndromes known to be both more
common in obese individuals and associated with impaired
insulin action independent of obesity (19), the estimates of
the relationship between obesity and insulin resistance are
applicable only to individuals without any disease known to
affect insulin action.
Figure 2. Graphic representation of the relationship between body mass index (BMI), steady-state plasma glucose, and coronary heart disk risk factors for
regression model B. Dependent variables: coronary heart disease risk factors (age, systolic blood pressure, diastolic blood pressure, total cholesterol,
triglycerides, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, glucose response, and insulin response). Independent
variables: BMI, steady-state plasma glucose, and the interaction term. RB  multiple correlation coefficient for the analyses based on regression model B.
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One important caveat that must be made as to our
estimate of the magnitude of the relationship between
obesity and insulin-mediated glucose disposal is the use of
BMI as the measure of obesity. This decision was based
upon our attempt to relate our findings to the NHANES III
results, but it should be noted that the conclusions of the
EGIR investigators (4) was independent of the estimates of
obesity used in that “neither the waist circumference, nor
the waist-to-hip ratio, indices of body fat distribution, was
related to insulin sensitivity after adjustment for age, gender,
and BMI.”
Relationship between obesity, insulin resistance, and
type 2 diabetes. The results of this study provide relevant
information concerning the link between obesity and insulin
resistance and the development of type 2 diabetes. Several
prospective studies have shown that degree of insulin
resistance and/or hyperinsulinemia are strong predictors of
type 2 diabetes in normal glucose tolerant individuals
(20–25). It is obvious from Figure 2 that, at any given BMI,
the most insulin-resistant tertile had plasma insulin concen-
trations that were three to four times higher than those in
the most insulin-sensitive tertile. It should also be noted
that the individuals in the most insulin-resistant tertile were
also the most glucose intolerant, a change that also increases
their risk of developing type 2 diabetes (20). Based upon
these considerations, it can be concluded that overweight/
obese individuals are not at equal risk to develop type 2
diabetes, and those in the lowest insulin-resistant tertile are
at less risk of developing type 2 diabetes than an insulin-
resistant individual of any weight.
Relationship between obesity, insulin resistance, and
CHD. The results presented also provide considerable
insight into the relationship between obesity, insulin resis-
tance, and CHD risk. Insulin resistance and/or compensa-
tory hyperinsulinemia have been shown to predict CHD in
nondiabetics (26–30), although it is not clear if this is a
direct effect or secondary to the risk factors present in these
individuals (31). The metabolic abnormalities most closely
related to insulin resistance are hyperinsulinemia, some
degree of glucose intolerance, hypertriglyceridemia, and a
low HDL cholesterol concentration (31), changes that have
been shown to increase CHD risk (26–34). In our study we
have demonstrated that, for a given level of obesity, these
metabolic abnormalities are clearly accentuated in the most
insulin-resistant tertile (Table 3 and Fig. 2). Thus, whether
it is insulin resistance, per se, or its most common manifes-
tations that increase CHD risk in insulin-resistant individ-
uals, these changes are not present in obese individuals who
are insulin-sensitive.
Conclusions. The results presented have reaffirmed the
fact that the greater the BMI, the more insulin-resistant the
individual. At the same time our results show that over-
weight/obese individuals can be insulin-sensitive and that
normal weight subjects can be insulin-resistant. In addition,
we have differentiated between the relative impact of over-
weight/obesity and insulin resistance on CHD risk factors,
demonstrating that insulin resistance at any given BMI
accentuates the risks of both type 2 diabetes and CHD.
Implications of these findings are self-evident; the most
intensive efforts to reduce risk of type 2 diabetes and CHD
in overweight/obese individuals should be focused on those
individuals who are also insulin-resistant.
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